[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-dysfunction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,45,66,88,115,148,179,202,234,262,295,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100644582","fmt-for-90-day-outcome-of-clinical-use-in-icu-sepsis-100644582",false,"NCT07670299","FMT for 90-Day Outcome of Clinical Use in ICU Sepsis","Fecal Microbiota Transplantation for 90-Day Outcome of Clinical Use in ICU Sepsis: a Single-Center, Open-Label, Randomized Controlled Trial","FOCUS","Inclusion Criteria:\n\n* Age ≥ 18 years, any ethnicity, any gender.\n* Diagnosis of sepsis according to the Sepsis-3 criteria (infection with an acute change in SOFA score ≥ 2 points).\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Patients whom the attending clinician considers to have a high risk of death within 5 days, or patients with treatment limitations in place.\n* Active major gastrointestinal bleeding, perforation, or other severe impairment of the intestinal barrier.\n* Patients unable to tolerate enteral nutrition meeting ≥50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stricture, severe gastrointestinal bleeding, or high-output intestinal fistula.\n* Planned or recent abdominal surgery (within 14 days).\n* Current diagnosis of fulminant colitis or toxic megacolon.\n* Recent receipt of high-risk immunosuppressive or cytotoxic therapy, such as rituximab, doxorubicin, or moderate-to-high-dose corticosteroids (≥20 mg\u002Fday of prednisone or equivalent) for more than 4 consecutive weeks.\n* Pregnant or breastfeeding women.\n* Participation in another clinical trial as a subject at the time of enrollment or within 3 months prior to enrollment.\n* Subjects for whom the validity of informed consent is questionable, including those with psychiatric disorders, intellectual disability, poor motivation, or other conditions that may limit their ability to provide informed consent.","ALL","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, representing one of the leading causes of death in intensive care units (ICUs) worldwide. Gut microbiota disruption is increasingly recognized as a key driver of persistent inflammation and multiple organ dysfunction in septic patients. Fecal microbiota transplantation (FMT) has emerged as a promising approach to restore gut microbial homeostasis. This study hypothesizes that FMT acts not through long-term engraftment of donor microbes, but via a \"functional pulse\" - a potent, transient biological intervention that delivers high-dose microbial metabolites (e.g., short-chain fatty acids), competitively inhibits pathogens, and rapidly modulates intestinal immune cell functions.\n\nThis is a single-center, open-label, randomized controlled trial conducted in the ICU of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. A total of 60 adult patients diagnosed with sepsis according to Sepsis-3 criteria within 24 hours of ICU admission will be randomized in a 1:1 ratio to receive either ICU standard care alone (control group) or ICU standard care plus FMT administered via a nasojejunal tube for three consecutive days (intervention group). The primary endpoint is all-cause mortality at 90 days. Secondary endpoints include ICU mortality, in-hospital mortality, 28-day mortality, changes in gut microbiota composition and metabolites, serum citrulline levels as a marker of intestinal barrier function, Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, vasopressor requirements, C-reactive protein and procalcitonin levels, fluid balance, incidence of ICU delirium and feeding intolerance, and 90-day hospital readmission rate. Safety outcomes include gastrointestinal symptoms and transient fever.",[28,29,30,31,32],"Sepsis","Critical Illness","Gastrointestinal Dysfunction","Dysbiosis","Fecal Microbiota Transplantation","NOT_YET_RECRUITING","2026-06-25",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":22},"2026-07-15",{"date":41,"type":22},"2028-10-15",{"name":43,"class":44},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100641753","oliceridine-for-gastrointestinal-dysfunction-100641753","NCT07650812","Oliceridine for Gastrointestinal Dysfunction","The Effect of Oliceridine on Gastrointestinal Dysfunction and Pain Management in Patients Undergoing Neurosurgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients undergoing selective neurosurgical resection of craniocerebral tumors;\n* Age ≥ 18 years old;\n* American Society of Anesthesiologists (ASA) grade 1-3;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients unable to complete scale assessment due to preoperative language dysfunction or communication impairment;\n* Patients with preoperative symptoms of posterior cranial nerve injury and who need to retain a tracheal tube;\n* Patients with insular, brainstem, or medullary lesions that may impair early postoperative recovery of consciousness;\n* Patients undergoing intracranial lesion resection via the transsphenoidal approach;\n* Patients with a history of previous abdominal surgery;\n* Patients with BMI \\> 35.0 kg\u002Fm2;\n* Patients with liver or kidney dysfunction;\n* Patients with a history of allergic or adverse reactions to the test drug;\n* Patients with a history of drug abuse;\n* Pregnant or lactating women.",{"count":53,"type":22},176,[25],"Gastrointestinal dysfunction is common in patients after major surgery, especially for neurosurgery. It was reported 80% of neurosurgery patients could be combined with gastrointestinal dysfunction, and it may relate to old age, surgery time, and factors of anesthesia and surgery. Meanwhile, postoperative constipation, nausea, and vomiting induced by gastrointestinal dysfunction may increase the intracranial bleeding. Oliceridine could activate mu opioid receptors without the interaction of (beta)arr2-muOR, and may reduce the gastrointestinal dysfunction, but a limited study has illustrated this topic. Thus, this study is conducted to explore whether oliceridine could reduce the gastrointestinal dysfunction vs. sufentanil in patients undergoing neurosurgery.",[30],"2026-06-14",{"date":59,"type":37},"2026-06-16",{"date":61,"type":22},"2026-07-01",{"date":63,"type":22},"2027-12-30",{"name":65,"class":44},"Beijing Tiantan Hospital",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100642882","fmt-for-feeding-intolerance-due-to-gastrointestinal-dysfunction-in-critically-ill-patients-100642882","NCT07640633","FMT for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients","Fecal Microbiota Transplantation for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients: A Single-Center, Single-Blind, Randomized Controlled Trial","FMT-FIT","Inclusion Criteria:\n\n1. Aged 18 to 70 years inclusive, regardless of ethnicity or gender;\n2. Female participants are either non-fertile (i.e., physiologically incapable of pregnancy, including women with ≥2 years of menopause) or have no pregnancy plans;\n3. Have been admitted to the ICU for ≥24 hours;\n4. Expected ICU stay ≥7 days after study enrollment;\n5. Screened positive for ≥1 manifestation of gastrointestinal dysfunction (intra-abdominal hypertension \\[IAH\\], massive gastric retention, diarrhea, lower gastrointestinal paralysis, bowel dilatation); enteral nutrition is then implemented under the guidance of the enteral feeding intolerance (FI) score, and participants with persistent FI after a 3-day trial are formally enrolled;\n6. Participants can actively cooperate or passively complete relevant examinations and follow-up procedures;\n7. Have signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe systemic infection in the early resuscitation phase, with hemodynamic instability, insufficient tissue perfusion, or severe fluid-electrolyte and acid-base imbalances;\n2. Patients assessed by clinicians as having a high risk of death within 5 days, or those with restricted treatment decisions;\n3. Active gastrointestinal bleeding, perforation, or other conditions with severe intestinal barrier impairment;\n4. Patients unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stenosis, massive gastrointestinal bleeding, or high-output enterocutaneous fistula;\n5. Planned or recent abdominal surgery (within 14 days prior to enrollment);\n6. Current diagnosis of fulminant colitis or toxic megacolon;\n7. Neutropenia (neutrophil count \\\u003C 1500 cells\u002FµL);\n8. Patients with congenital or acquired immunodeficiency disorders;\n9. Recent receipt of high-risk immunosuppressive or cytotoxic agents, e.g., rituximab, doxorubicin, or medium-to-high-dose corticosteroids (≥ 20 mg\u002Fday prednisone equivalent) for a duration of \\> 4 weeks;\n10. Pregnant or lactating women;\n11. Participation in another clinical trial as a subject at the time of enrollment or within 3 months prior to enrollment;\n12. Doubtful validity of informed consent: subjects with mental illness, intellectual disability, poor motivation, or other factors that restrict the validity of informed consent for participation in this study.",{"count":21,"type":22},[25],"Critically ill patients admitted to the intensive care unit (ICU) frequently present with gastrointestinal dysfunction and are at elevated risk of malnutrition. Gastrointestinal dysfunction is correlated with adverse clinical outcomes, including prolonged mechanical ventilation duration, extended ICU length of stay, and increased 90-day mortality.\n\nIn critically ill ICU patients, severe gut microbiota dysbiosis and intestinal barrier impairment may occur due to the burden of primary critical illnesses, as well as the administration of proton pump inhibitors and antibiotics. This cascade contributes to a high prevalence of gastrointestinal dysfunction, alongside profound gut-derived systemic inflammatory responses and organ damage. Given the pivotal role of gut microbiota in maintaining intestinal homeostasis, fecal microbiota transplantation (FMT) holds promise as a novel therapeutic strategy for enteral feeding intolerance secondary to gastrointestinal dysfunction in critically ill ICU patients.\n\nThis study intends to deliver FMT via a nasojejunal tube to critically ill patients with gastrointestinal dysfunction admitted to the ICU. Its objectives are to evaluate the intervention's effects on gastrointestinal function recovery and the alleviation of enteral feeding intolerance, while also assessing its impacts on intestinal barrier function, gut microbiota composition and metabolic profiles, serum metabolite signatures, immune-inflammatory responses (including lymphocyte subsets, cytokines, C-reactive protein, and procalcitonin), ICU delirium, ICU sleep quality, and clinical outcomes (encompassing ICU mortality, in-hospital mortality, 28-day all-cause mortality, 90-day all-cause mortality, 90-day readmission rate, and 90-day incidence of secondary infections).",[78,30,79],"Feeding Intolerance","Critically Ill Intensive Care Unit Patients","2026-06-05",{"date":82,"type":37},"2026-06-11",{"date":61,"type":22},{"date":85,"type":22},"2027-06-30",{"name":43,"class":44},1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":87},"100640485","postoperative-gi-dysfunction-and-nutrition-in-malnourished-cancer-surgery-patients-100640485","NCT07622888","Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients","Gastrointestinal Dysfunction, Nutritional Status, and Delirium in the Early Postoperative Period in Oncologic Surgical Patients With Pre-existing Malnutrition: A Prospective Two-Center Observational Cohort Study","GIDNUT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed malignant tumor of the abdomen or pelvis with planned radical or cytoreductive surgery.\n* Baseline malnutrition defined as NRS2002 ≥ 3 and at least one phenotypic and one etiologic GLIM criterion.\n* Expected postoperative hospitalization ≥ 7 days.\n* Ability to undergo baseline cognitive and nutritional assessments (MoCA, NRS2002, GLIM, PG-SGA) prior to surgery.\n* Signed informed consent for participation and data collection.\n\nExclusion Criteria:\n\n* Severe decompensated hepatic or renal failure rendering surgery infeasible.\n* Documented preexisting severe cognitive impairment or dementia precluding valid postoperative cognitive\u002Fdelirium assessment (e.g., MoCA \\\u003C 18 or documented dementia).\n* Pregnancy or breastfeeding.\n* Participation in another interventional randomized clinical trial within the prior 30 days that could confound outcomes.\n* Inability to ensure postoperative follow-up or reliable data collection (planned transfer without access, loss of contact).",{"count":97,"type":22},120,"OBSERVATIONAL","This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and\u002For pelvic oncologic surgery with pre-existing malnutrition. The study describes the course of postoperative gastrointestinal dysfunction and evaluates whether real-world exposure to parenteral serotonin as part of routine postoperative care is associated with a higher proportion of patients whose gastrointestinal dysfunction regresses to LIFE score less than or equal to 1 by postoperative day 5 (plus or minus 1 day), compared with patients not exposed to serotonin.\n\nAll treatment decisions, including the use of parenteral serotonin, metoclopramide, neostigmine, nutritional support, and other postoperative management, are made solely by the treating physicians in accordance with routine clinical practice. The protocol does not assign, randomize, require, or restrict any drug treatment; it records real-world care, daily LIFE assessments during postoperative days 1 through 7, nutritional status measures, body composition where available, delirium screening, complications, length of stay, and mortality.",[30,101,102,103,104],"Malnutrition","Delirium - Postoperative","Abdominal Neoplasm","Pelvic Neoplasm","2026-05-31",{"date":107,"type":37},"2026-06-03",{"date":109,"type":22},"2026-10-01",{"date":111,"type":22},"2029-03-01",{"name":113,"class":114},"Arma Ltd.","INDUSTRY",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":87},"100625408","prognosis-and-diagnosis-of-acute-gastrointestinal-dysfunction-in-cardiac-surgery-patients-100625408","NCT07422246","Prognosis and Diagnosis of Acute Gastrointestinal Dysfunction in Cardiac Surgery Patients","PREDICT-GICS","Inclusion Criteria:\n\n* Surgery on the heart and main vessels with a high risk of developing gastrointestinal dysfunction (according to literature data and our own retrospective study);\n* Patient's consent to participate in the study\n\nExclusion Criteria:\n\n* Patient's refusal to participate in the study;\n* HIV infection in the patient;\n* Immunosuppressive therapy;\n* Oncological disease;","95 Years",{"count":124,"type":22},100,[25],"The purpose of this prospective observational clinical cohort study is to develop a scientifically based approach to the prediction and early diagnosis of intestinal dysfunction in cardiac surgery patients.\n\nThe main questions that the study should answer:\n\nWhat are the main risk factors for the development of intestinal dysfunction? What specific and non-specific biomarkers can predict the development of intestinal dysfunction? The study participants will be monitored from the moment of hospitalization until the end of their stay in a medical facility",[30,128,129,130],"Cardiac Surgery Intensive Care Treatment","Cardiac Surgery","Cardiac Surgery in Adult Patient",[132,133,134,135,136,137,138],"cardiac surgery","intestinal dysfunction","gastrointestinal dysfunction","gastrointestinal complications","multiorgan dysfunction syndrome","intestinal failure","gastrointestinal failure","2026-02-18",{"date":141,"type":37},"2026-02-19",{"date":143,"type":22},"2026-03-10",{"date":145,"type":22},"2028-09-30",{"name":147,"class":44},"Petrovsky National Research Centre of Surgery",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":178},"100612324","effect-of-hfnc-on-incidence-of-hypoxia-during-sedated-gastrointestinal-endoscopy-in-critical-patients-100612324","NCT07252102","Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients","Effect of High Flow Nasal Cannula Oxygenation on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients: A Multicentre Randomised Controlled Trial","Inclusion Criteria:\n\n1. 18≤ age ≤80, gender is not limited;\n2. Patients undergoing elective gastroenteroscopy or treatment;\n3. ASA grade Ⅲ\\~Ⅳ;\n4. 18 kg\u002Fm2≤BMI≤28kg\u002Fm2;\n5. The operation time of gastroenteroscopy is expected to be no more than 60min;\n6. Clearly understand, voluntarily participate in the study, and have informed consent from myself or my family members.\n\nExclusion Criteria:\n\n1. Patients with nasal congestion, nasal bleeding, recent nasal trauma, recent nasal surgery, increased intracranial pressure and skull fracture, etc., who can not perform high-flow nasal catheter oxygen;\n2. acute respiratory infections and asthma attacks;\n3. Patients diagnosed with COPD;\n4. Clear difficult airway;\n5. Acute upper gastrointestinal bleeding with shock;\n6. Gastrointestinal obstruction with gastric content retention;\n7. Allergic to sedatives such as propofol;\n8. Persons with no capacity for civil conduct such as cognitive dysfunction.","80 Years",{"count":157,"type":22},450,[25],"High flow nasal cannula oxygenation (HFNC) offers high flow and concentration oxygen delivery, providing excellent non-respiratory oxygenation. As a relatively new oxygen delivery method, it has gained widespread use. We have demonstrated that high flow nasal cannula oxygenation reduce the incidence of hypoxia during sedated gastrointestinal endoscopy in patients with American Anesthesiologist Rating (ASA rating) grades 1 to 2 and obesity. We hypothesized that HFNC could mitigate the risk of hypoxia in critical patients during sedated gastrointestinal endoscopy. To confirm this, we selected critical patients with ASA grades 3 to 4 who were scheduled for gastrointestinal endoscopy. We observed and compared the incidence of hypoxia (75%≤SpO2 \\\u003C 90% and \\\u003C 60S), severe hypoxia (SpO2\\\u003C75% for any duration or 75%≤SpO2 \\\u003C 90%, ≥60s), subclinical respiratory depression (90%≤SpO2 \\\u003C 95%), respiratory-related adverse events, sedation-related adverse events, and complications associated with high flow nasal cannula oxygenation using HFNC or regular nasal cannula during the sedated gastrointestinal endoscopy.",[161,162,30],"Liver Cirrhosis","Polyps of Colon",[164,165,166,167],"critical patients","HFNC","High flow nasal cannulas oxyge","hypoxia","RECRUITING","2026-01-16",{"date":171,"type":37},"2026-01-20",{"date":173,"type":37},"2025-11-20",{"date":175,"type":22},"2026-12-30",{"name":177,"class":44},"Zhejiang University",3,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100465722","low-pressure-pneumoperitoneum-and-postoperative-ileus-100465722","NCT05344417","Low Pressure Pneumoperitoneum and Postoperative Ileus","Impact of Low Pressure Pneumoperitoneum on Postoperative Ileus and Gastrointestinal Dysfunction in Patients Undergoing Laparoscopic Large Bowel Surgery","Inclusion Criteria:\n\n1. Adult patients \\> 18 years old of both sexes who consent to participate in the study and do not have any of the exclusion criteria.\n2. Patients undergoing laparoscopic right hemicolectomy to remove tumors.\n3. Patients undergoing sigmoid resection to remove polyps, diverticula or tumors.\n\nExclusion Criteria:\n\n1. History of inflammatory bowel disease.\n2. History of intestinal ischemia.\n3. History of intestinal adhesions and adhesive disease.\n4. Patients with a history of bowel resection or major abdominal surgery in the past. Appendectomies and hernia repairs are not considered exclusion criteria.\n5. Patients having epidural catheters placed for postoperative pain control for the study period. Intrathecal morphine injections for postoperative pain control will not exclude the patients from the study.\n6. Significant acid-base and electrolyte imbalance before surgery as determined by the study personnel at the screening stage.\n7. Allergy to or contraindications to rocuronium, or sugammadex.\n8. Patients affected by medical conditions or receiving drugs that may prolong or shorten the duration of rocuronium effect (i.e. aminoglycosides, magnesium).\n9. Significant comorbid conditions as determined by the study personnel at the screening stage.\n10. Patients receiving any drugs that may significantly alter the picture of postoperative ileus (determined by the investigators) will be excluded from the study.\n11. Prisoners and pregnant patients",{"count":187,"type":22},125,[25],"The investigators are testing the hypothesis that lower pressure pneumoperitoneum during laparoscopic large bowel surgery protects the bowel from postoperative ileus and bowel dysfunction leading to faster recovery and discharge from the hospital. Our study will focus on the effects of high or low intraperitoneal pressure as well as pressure variations on the course of postoperative ileus, time to hospital discharge, and postoperative gastrointestinal dysfunction in adult patients undergoing laparoscopic large bowel resection (i.e., sigmoidectomy and right colectomy). A randomized parallel group study will be conducted involving 5 arms of surgical patients to test whether differences on postoperative ileus outcome parameters occur between high (15 mm Hg) and low pressure pneumoperitoneum (8-12 mm Hg), as well as whether there are differences between the 2 insufflation devices that provide constant or variable intrabdominal pressure throughout the laparoscopic surgery. For high pressure pneumoperitoneum, either neostigmine or sugammadex are used for reversal of moderate neuromuscular blockade. For low pressure pneumoperitoneum, sugammadex is used for reversal of deep neuromuscular blockade. The investigators plan to use 2 types of gas insufflation devices, one of which will provide a relatively stable pressure level throughout surgery (AirSeal® device), and the second one will provide a more variable pressure (Olympus standard insufflation device). Using both pressure modalities, the investigators will study the effects of different pressure characteristics on the course of postoperative ileus, duration of in-hospital treatment, pain level, and the stability of hemodynamic and respiratory parameters during surgery. Changes in intrabdominal pressure during the surgery will be monitored and recorded using a custom software for later analysis of fluctuations in pressure to relate them to outcomes. Other parameters will be obtained from EPIC (IHIS) medical charts. In addition, clinical data on postoperative ileus will be correlated with experimental outcomes from in vitro exploratory studies done using human samples of peritoneal lavage fluid, serum, and a small portion of the surgically removed bowel from each patient (that is otherwise discarded). A panel of inflammatory markers will be analyzed and biochemical, imaging, histological, immunochemical, molecular signaling, and glial activation studies will be done to evaluate the potential mechanisms of dysfunction associated with postoperative ileus.",[191,30],"Postoperative Ileus","2025-10-31",{"date":194,"type":37},"2025-11-03",{"date":196,"type":37},"2024-03-06",{"date":198,"type":22},"2027-07-31",{"name":200,"class":44},"Ohio State University",2,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":87},"100587811","phase-1-efficacy-of-fuzheng-tongfu-jiedu-prescription-for-treating-gastrointestinal-dysfunction-associated-with-sepsis-100587811","NCT06933238","Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis","The Clinical Effect and Mechanism of Fuzheng Tongfu Jiedu Prescription Regulating Cell Pyrodeath in the Treatment of Gastrointestinal Dysfunction in Sepsis Based on mtDNA\u002FNLRP3\u002FCaspase-1\u002FGSDMD Signaling Pathway","FZTFJD","Inclusion Criteria:\n\n1. Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III.\n2. 50-90 years old, regardless of gender.\n3. Sequential Organ Failure Assessment (SOFA) score ≥ 2.\n4. Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours.\n5. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible.\n2. Patients with allergies or allergic constitution to the investigational herbal medications.\n3. Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight \\> 150 kg), trauma, or surgical factors.\n4. Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc.\n5. History of gastrointestinal surgery.\n6. Long-term use of corticosteroids or immunosuppressants.\n7. Severe psychiatric disorders or inability to cooperate with trial protocols.\n8. Participation in other clinical trials within 30 days.\n9. Pregnant or lactating women.\n10. Participated in other clinical studies in the past 3 months.","50 Years","90 Years",{"count":213,"type":22},70,[215,216],"PHASE1","PHASE2","This study is a single-center, randomized, double-blind, placebo-controlled trial.",[219,30,220],"Sepsis Abdominal","Traditional Chinese Medicine",[134,222,223,224],"sepsis","Traditional Chinese medicine","Fuzheng Tongfu Jiedu Decoction","2025-04-11",{"date":227,"type":37},"2025-04-18",{"date":229,"type":22},"2025-04-25",{"date":231,"type":22},"2026-06-30",{"name":233,"class":44},"Dongzhimen Hospital, Beijing",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":241,"sex":17,"minAge":242,"maxAge":19,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":87},"100573025","phase-2-evaluating-perioperative-outcomes-dexmedetomidine-vs-lignocaine-in-laparoscopic-chlolecystectomy-100573025","NCT06740903","Evaluating Perioperative Outcomes: Dexmedetomidine vs Lignocaine in Laparoscopic Chlolecystectomy","Comparison of Dexmedetomidine & Lignocaine Infusion on Perioperative Hemodynamics, Postoperative Analgesia & Recovery of Postoperative Gastrointestinal Function in Patients for Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n1. Patients of age 20-70 years\n2. Both gender\n3. Laparoscopic cholecystectomy under general Anaesthesia\n4. ASA I-II.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Patients with history of allergic reaction to trial drugs\n* Patients with cardiovascular disease, sickle cell disease, psychiatric disorder, peripheral vascular disease, and neurological diseases (on medical record)\n* Anemia\n* Patient on TCA or Beta blocker drugs.\n* Uncontrolled hypertension (P≥160\u002F100 mmHg)\n* Uncontrolled diabetes mellitus\n* Obesity BMI \\> 35",true,"20 Years",{"count":244,"type":22},140,[216,246],"PHASE3","Nowadays laparoscopic surgery is the first choice for many surgeries. Such surgeries have revolutionized the surgical practice and has markedly reduced the incidence of intraoperative and postoperative complications. To minimize these side effects associated with the use of opioids, various methods have been adopted. Recently, different trials have highlighted the possible role of dexmedetomidine and lignocaine in providing postoperative analgesia and attenuating hemodynamic response. Literature showed conflicting results regarding both these drugs. So, we want to find the evidence for local setting. This Randomized Controlled Trial will be done at Department of Anesthesia, Sahiwal teaching hospital, Sahiwal for 12 months. Sample size of 140 cases; 70 cases in each group will be included through non-probability consecutive sampling. Then patients will be divided in two groups by using computer generated random number table. In group A, patients will be given dexmedetomidine infusion. In group B, patients will be given lignocaine infusion. All anesthesia procedures will be done by researcher. Heart rate and mean arterial pressure will be assessed before induction of anesthesia, after every 10 mins every 30 mins till completion of surgery. Total operative time will be noted. After procedure, patients will be assessed for postoperative pain score. when pain will be ≥4 on visual analogue scale rescue analgesia will be given and time will be noted. Total duration from time of surgery till need for rescue analgesia will be noted. Duration of postoperative analgesia opioid consumption \u002F24 hrs.) will be presented by using mean± SD.",[249,250,30,251],"Hemodynamics Instability","Post Operative Pain","Cholecystitis","2024-12-14",{"date":254,"type":37},"2024-12-18",{"date":256,"type":37},"2024-08-06",{"date":258,"type":22},"2025-09-06",{"name":260,"class":261},"Sahiwal medical college sahiwal","OTHER_GOV",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":87},"100555304","achieving-nutritional-target-in-critically-ill-patients-with-impaired-gastrointestinal-dysfunction-100555304","NCT06510348","Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNtesTinal Dysfunction","ATTAINMENT","Inclusion Criteria:\n\n* All adults (\\> 18 years old)\n* Mechanical ventilation for more than four days,\n* Controlled shock state (hemodynamic and tissue perfusion goals are reached) - Impaired intestinal absorbtion, defiend by both ultrasound measurement of gastric residual volume and paracetamol absorbtion test\n\nExclusion Criteria:\n\n* patients on non-invasive mechanichal ventilation\n* contraindication for EN for \\> 48 h after admission\n* patients with gastrointestinal surgical intervention within 3 months,\n* history of malabsorption, inflammatory bowel disease\n* short bowel syndrom\n* anorexia nervosa\n* gastrointestinal bleeding\n* cirrhosis\n* traumatic brain injury\n* subarahnoidal hemorrhage\n* neoplasia\n* post cardiac arrest patients\n* patients on chronic therapy with corticosteroids\n* pregnant women.",{"count":270,"type":22},164,[25],"Clear study hypothesis \u002F research question\n\nIt has already been proven that a prolonged negative energy balance during intensive care stay is an independent risk factor for mortality. Although it was thought that achivieng optimal delivery of calories will prevent nutritional deficits in critically ill patients, published randomized controlled trials failed to confirm this hypothesis.\n\nCombinging enteral and parenteral support may be an efficent strategy to reach nutritional target in critically ill patients. According to the current guidelines the use of suplemental parenteral nutrition (SPN) should be considered when energy targets are not achieved by enteral (EN) route, however, no clear data regarding timing, amount and composition is specified. Moreover, based on recente published data overfeeding should also be avoided, considering the negative impact on outcome.\n\nNutritional support for critically ill patients was focused more on preventing caloric and protein deficits and no great emphasis was placed on the efficiency of intestinal absorption. Gastrointestinal dysfunction is a prevalent reported complication that may contribute to falling short of meeting nutritional goals. This encompasses a wide spectrum of symptoms, such as impaired gastric emptying, ileus or impaired intestinal absorbtion, exposing patients to feeding intolerance, malnutrition and worse outcomes. No standard definition and monitoring techniques are so far available for the diagnostic of feeding intolerance. Although increased gastric residual volume (GRV) is the most used parameter for highlighting feeding intolerance, a controversy regarding the adequate threshold of GRV persists. Acetaminophen absorption test has been previously proposed as a diagnostic tool to asses impaired gastric emptying and intestinal absorbtion.\n\nBesides intestinal absorbtion, efficient utilization of macronutients should also be assessed, considering that critically ill patients have varying metabolic conditions and may not be able to metabolically handle adminsitered substrates. As a result body composition analysis should be taken into account in order to obtain a dynamic quantification, especially, of the mucle mass compartiments.\n\nTherefore the following low-interventional study is designed to investigate the hypothesis regarding energy and protein intake achievement in critically ill patients with diagnosed impaired gastrointestinal dysfunction to whom tailored nutritional support is administered.\n\nTaking into account that we aim to identify patients with early-phase gastrointestinal dysfunction impaired gastric emptying and reduced intestinal absorbtion (diagnosed using ultrasound gastric residual volume and byacetaminiphen absorbtion test) will serve as defining factors. Patients will be randomized to receive nutritional support either according to the EN protocol or enteral trophic feed + SPN protocol.\n\nDifferences in rectus femoris thickness measured on admission, on day 10 and 15, variation of lean body mass measured by bioelectrical impedance on admission on day 10 and 15, and differences between groups in muscle function using handgrip dynamometer will also be evaluated in both groups.",[274,275,30,276,29],"Parenteral Nutrition","Gastroparesis","Protein Deficiency",[134,278,279,280,281,282,283,284,285],"supplemental parenteral nutrition","parenteral nutrition","enteral nutrition","critically ill","protein intake","calorie intake","gastroparesis","malabsorption","2024-11-04",{"date":288,"type":37},"2024-11-06",{"date":290,"type":37},"2024-10-01",{"date":292,"type":22},"2026-12-31",{"name":294,"class":44},"Romanian Society for Enteral and Parenteral Nutrition",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":304,"conditions":305,"keywords":310,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":87},"100555598","gastrointestinal-dysfunction-in-aortic-surgery-patients-100555598","NCT06514170","Gastrointestinal Dysfunction in Aortic Surgery Patients","Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.","Inclusion Criteria:\n\n* 18 years of age or older.\n* Patients after surgical interventions (elective or urgency) on the aorta with cardiopulmonary bypass.\n* Invasive mechanical ventilation expected to be required more than 48 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under mechanical ventilation with pre-existing gastrointestinal issues.\n* Diagnosis of adult congenital heart disease.\n* Ongoing pregnancy or lactation period.\n* Simultaneous participation in another clinical study involving experimental therapy.\n* Presence of chronic intestinal disease.\n* Previous gastrointestinal conditions detected during nutritional screening.",{"count":303,"type":22},114,"The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary \\[calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)\\] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.",[306,30,307,308,309],"Aortic Aneurysm","Aortic Diseases","Enteral Feeding Intolerance","Surgical Complication",[311,312,313],"Gastrointestinal dysfunction","Aortic diseases","Aorta surgery","2024-07-23",{"date":316,"type":37},"2024-07-24",{"date":314,"type":37},{"date":319,"type":22},"2026-06",{"name":321,"class":44},"Instituto Nacional de Cardiologia Ignacio Chavez",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":241,"sex":17,"minAge":18,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100551906","determination-of-the-safety-and-efficacy-of-two-probiotic-strains-100551906","NCT06466174","Determination of the Safety and Efficacy of Two Probiotic Strains","Determination of the Safety and Efficacy of Two Probiotic Strains in Adults With Mild to Moderate Gastrointestinal Discomfort","CODECS","Inclusion Criteria:\n\n1. Signed Informed consent form\n2. Healthy adults aged 18-65 years\n3. Subclinical mild to moderate gastrointestinal complaints (GSRS-IBS score 20-45 at baseline)\n\nExclusion Criteria:\n\n1. Presence of a serious congenital anomaly or chronic medical condition that would contraindicate participation, including history of major gastrointestinal surgery, chronic gastrointestinal illness, abnormal intestinal anatomy or significant abdominal disorder\n2. Severe chronic illnesses\n3. Known immunodeficiency\n4. Use of immunosuppressive agents (corticosteroids, methotrexate…)\n5. Presence of severe immunodeficient family members as provided by subjects self-report\n6. Pregnancy, 6 months postpartum period or current breastfeeding\n7. Women of childbearing age planning pregnancy during the course of the study\n8. Actively participating in another clinical study, having completed a clinical study in the past 60 days or being in the exclusion period of a previous clinical study\n9. Not able to understand and comply with requirements of the study\n10. Use of probiotics, prebiotics, postbiotics, antibiotics within 3 weeks of study commencement","65 Years",{"count":124,"type":22},[25],"The goal of this study is to determine the safety and efficacy of two probiotic strains in adults with mild to moderate gastrointestinal discomfort. The main questions it aims to answer is whether 6-week administration of a probiotic can improve how the participant feels regarding their gut health. This is done by completing a weekly questionnaire and the results are compared between the 6 weeks the participants are on a placebo and the 6 weeks the participants are on the probiotic. Participants will also provide a blood sample, and stool sample at the start and end of each treatment. Similarly, the results from the blood samples and stool samples will be analysed to determine if there is any improvement in markers related to gut health.",[30],[336,337],"probiotic","gastrointestinal discomfort","2024-06-17",{"date":340,"type":37},"2024-06-20",{"date":342,"type":22},"2024-06",{"date":344,"type":22},"2026-05",{"name":346,"class":114},"The Archer-Daniels-Midland Company"]